Each material 8-K filed by a company listed on a US stock exchange (NYSE, Nasdaq, Cboe), read and summarized: what happened, the key numbers, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). This page lists the last 45 days; every brief stays on its company's 8-K page (3616 companies, A–Z).
Polar Power received written confirmation from Nasdaq that it complies with the $2.5 million minimum stockholders' equity requirement. The company also announced Phase 2 of its restructuring, which targets further facility consolidation and lower fixed overhead, and it is evaluating refinancing and other capital-raising options. Nasdaq said the company must keep showing compliance in its next periodic report or it may face delisting proceedings.
Nasdaq staff determined Polar complies with the $2.5 million minimum stockholders' equity requirement, based on its Form 8-K dated October 23, 2026
Phase 1 of the restructuring delivered about $1.03 million in annualized cost reductions; the target is about $2 million in total annualized savings, including Phase 1
Polar is evaluating refinancing and other capital-raising alternatives, and Nasdaq cautioned that delisting proceedings may follow if compliance is not evidenced in the next periodic report
uniQure N.V. said the FDA accepted its Biologics License Application for ifezuntirgene inilparvovec, an investigational gene therapy for Huntington's disease, and granted Priority Review with a PDUFA target action date of May 1, 2027. The FDA also said it is tentatively planning an Advisory Committee meeting, with dates to be set later, and the company and FDA have aligned on the design of a confirmatory trial.
FDA accepted the BLA under the Accelerated Approval pathway and granted Priority Review
PDUFA target action date is May 1, 2027
FDA tentatively plans to discuss the application at an Advisory Committee meeting; the company will be notified once the date is set
Confirmatory trial design: randomized, standard-of-care, about 200 patients in a 2:1 ratio, Total Functional Capacity at 36 months as primary endpoint; U.S. patient screening planned to start by end of 2026
INOVIO announced on October 30, 2026 that the FDA granted accelerated approval for VOCERYQ, a DNA-based immunotherapy, to reduce the frequency of surgery in adults with recurrent respiratory papillomatosis (RRP). The company expects to make the product available to order and ship in about 60 days and to deploy its full field team in the first quarter of 2027, and it must submit a draft confirmatory study protocol by the end of 2026. The filing does not disclose revenue, pricing, or financial projections, so the near-term financial effect on shareholders is not quantified.
FDA granted accelerated approval on October 30, 2026 for VOCERYQ in combination with the CELLECTRA 5PSP delivery device
In the efficacy population of 26 patients, 7 (27%) had a complete response after 12 months of follow-up, based on the RRP-001 study
Order-and-ship availability expected in about 60 days; full field deployment expected in Q1 2027 with Syneos Health support
Continued approval may depend on a confirmatory study; draft protocol due by end of 2026 and final protocol expected by mid-2027
Palvella Therapeutics said the FDA accepted for filing and granted Priority Review to its New Drug Application for QTORIN 3.9% rapamycin anhydrous gel for microcystic lymphatic malformations, with a Prescription Drug User Fee Act target action date of February 28, 2027. The company says the drug could be the first FDA-approved therapy for this condition and is preparing for a potential U.S. launch in the first half of 2027, but approval is not assured.
FDA accepted the NDA and granted Priority Review for QTORIN 3.9% rapamycin anhydrous gel
PDUFA target action date set for February 28, 2027
Phase 3 SELVA study met all six prespecified efficacy endpoints (all p<0.001)
Potential standalone U.S. commercial launch planned for the first half of 2027, subject to FDA approval
Aquestive Therapeutics said the FDA has accepted its resubmitted New Drug Application for Anaphylm as complete and classified it as a Class 2 response, with a PDUFA goal action date of March 16, 2027. The filing does not provide financial figures, and the outcome depends on the FDA's review, which the company says it expects to complete on or before the goal date.
FDA acknowledged the Anaphylm NDA resubmission as complete and classified it as a Class 2 response
PDUFA goal action date set for March 16, 2027
Aquestive submitted the resubmission on September 16, 2026, after a January 30, 2026 Complete Response Letter
Ex-U.S. submission to Health Canada remains on track for Q4 2026
Nasdaq's Hearings Panel granted SCWorx's request for reconsideration on October 2, 2026, found the company compliant with continued listing requirements, and approved continued listing on The Nasdaq Capital Market. Trading on Nasdaq, suspended since April 14, 2026, will resume on a date Nasdaq has yet to schedule, and the stock trades on the OTCQB until then. The approval carries a one-year Panel Monitor through October 2, 2027, and the company's private placement investors waived termination rights tied to the earlier delisting decision, though those rights revive if the delisting takes effect.
On October 2, 2026, the Panel granted reconsideration of its September 17, 2026 delisting decision and approved continued listing on The Nasdaq Capital Market
Publicly held shares rose to 549,092 as of September 17, 2026, after the September 16, 2026 private placement of 350,000 shares and related warrants
Nasdaq trading has been suspended since April 14, 2026; the stock stays on the OTCQB under WORX until Nasdaq sets a reinstatement date
If all purchasers terminated their purchases, the company would have to return an aggregate of $938,000 and the placement shares and warrants would be cancelled
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Frequently asked questions
Which filings get a brief?
Form 8-K filings by companies listed on a US stock exchange (NYSE, Nasdaq, Cboe; not over-the-counter stocks) that report a material event: results (Item 2.02), deals (1.01, 2.01), executive changes (5.02), restructuring (2.05), impairments (2.06), delisting notices (3.01), restatements (4.02), cybersecurity incidents (1.05), bankruptcy (1.03) and Regulation FD or other events (7.01, 8.01). Routine filings such as vote results or exhibits only are skipped.
How is the impact score set?
The AI rates each filing from 1 (routine) to 5 (major, such as a merger, bankruptcy or restatement) based only on what the filing says. It is a reading aid for sorting the day's filings, not a prediction of how the stock will move.
How quickly do briefs appear?
On weekdays the SEC filing feed is checked every 5 minutes from 6 am to 5:45 pm Eastern, when nearly all 8-Ks come in, and every hour after that until 10 pm. Briefs of the 1,000 largest companies follow within minutes; the others usually within the hour, or later the same day when many filings arrive at once.
Which companies are covered?
Every company with shares listed on the NYSE, Nasdaq or Cboe that files 8-Ks, about 4,500 of them. Foreign companies that report on Form 6-K instead are not included. The S&P 1500 only filter above narrows the list to the large, mid and small caps of the S&P Composite 1500.
Are older briefs kept?
Yes. This page shows the last 45 days, but every brief ever published stays online: each has its own page, and each company has an 8-K page listing all of its briefs, newest first, linked from its stock page and from the A-Z list of companies.